UP!
 |
|
|
Type
|
Public NASDAQ: NBIX |
|---|---|
| Industry | Biotechnology |
| Founded | 1992 |
| Headquarters | San Diego, California, U.S. |
|
Key people
|
Bill Rastetter, Chairman Kevin C. Gorman, CEO |
|
Number of employees
|
95 (2015) |
| Website | www.neurocrine.com |
Neurocrine Biosciences is a biopharmaceutical company founded in 1992 and located in San Diego, California. The company took its name from the original focus on therapies for neurological and endocrine diseases and disorders.
On May 16, 2006 when the Food and Drug Administration (FDA) denied approval for the 15-milligram dose of Indiplon, a medication to treat insomnia. Neurocrine had developed the drug and was seeking to market it with partner Pfizer. As a result of the denial, the stock price fell significantly and the company laid off 300 employees in 2006. In 2007 Neurocrine showed a fourth quarter loss of $128 million, including a $94 million write-off, with a further layoff of half the remaining workforce.
In 2010 the company announced that its drug to treat endometriosis had achieved its main and secondary goals in a study. The drug, called elagolix, reportedly showed statistically significant reductions in dysmenorrhea, or pelvic pain during menstruation as well as painful intercourse. As of 2016 the drug, being developed in cooperation with AbbVie, is in phase III clinical trials.
In April 2017 The United States Food and Drug Administration approved Ingrezza for the treatment of tardive dyskinesia. At the time of approval, it was the only drug that can treat tardive dyskinesia.
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q3 2022 | 2022-10-31 | Future report Set alerts | |
| Q2 2022 | 2022-08-04 | -0.18 | -0.18 |
| Q1 2022 | 2022-05-04 | 0.14 | 0.14 |
| Q4 2021 | 2022-02-11 | -0.08 | -0.08 |
| Q3 2021 | 2021-11-01 | 0.23 | 0.23 |
| Q2 2021 | 2021-08-03 | 0.43 | 0.43 |
| Q1 2021 | 2021-05-05 | 0.33 | 0.33 |
| Q4 2020 | 2021-02-04 | 0.72 | 0.72 |
| Q3 2020 | 2020-11-09 | 0.00 | 0.00 |
| Q2 2020 | 2020-08-03 | 0.81 | 0.81 |
| 2016-06-29 | Initiated Coverage | HC Wainwright | Buy | $80.00 |
| 2016-06-08 | Reiterated Rating | Jefferies Group | Buy | |
| 2016-06-07 | Reiterated Rating | Piper Jaffray | Overweight | $96.00 |
| 2016-06-07 | Reiterated Rating | Piper Jaffray Cos. | Overweight | $96.00 |
| 2016-06-01 | Reiterated Rating | Leerink Swann | Outperform | $63.00 |
| 2016-05-25 | Reiterated Rating | Jefferies Group | Buy | $61.00 |
| 2016-05-19 | Reiterated Rating | Jefferies Group | Buy | $58.00 |
| 2016-05-16 | Reiterated Rating | Piper Jaffray | Overweight | $96.00 |
| 2016-05-08 | Reiterated Rating | Jefferies Group | Buy | |
| 2016-05-08 | Reiterated Rating | Robert W. Baird | Buy | |
| 2016-05-04 | Reiterated Rating | JPMorgan Chase & Co. | Buy | |
| 2016-04-14 | Reiterated Rating | Jefferies Group | Buy | |
| 2016-04-12 | Reiterated Rating | BMO Capital Markets | Outperform | $57.00 |
| 2016-04-12 | Reiterated Rating | JPMorgan Chase & Co. | Buy | |
| 2016-04-06 | Initiated Coverage | BMO Capital Markets | Outperform | |
| 2016-04-04 | Reiterated Rating | Piper Jaffray | Overweight | $96.00 |
| 2016-03-28 | Reiterated Rating | Jefferies Group | Buy | $60.00 |
| 2016-02-12 | Reiterated Rating | Cowen and Company | Buy | $65.00 |
| 2016-02-11 | Reiterated Rating | Piper Jaffray | Overweight | $96.00 |
| 2016-02-09 | Reiterated Rating | JPMorgan Chase & Co. | Buy | $70.00 to $63.00 |
| 2016-01-22 | Reiterated Rating | Leerink Swann | Buy | $71.00 to $76.00 |
| 2015-11-04 | Reiterated Rating | Robert W. Baird | Buy | |
| 2015-11-02 | Boost Price Target | Nomura | Buy | $34.00 to $43.00 |
| 2015-11-02 | Boost Price Target | Deutsche Bank | Buy | $35.00 to $45.00 |
| 2015-11-02 | Boost Price Target | Cowen and Company | Outperform | $40.00 |
| 2015-11-02 | Boost Price Target | Nomura Holdings Inc. | Buy | $34.00 to $43.00 |
| 2015-11-02 | Boost Price Target | Deutsche Bank AG | Buy | $35.00 to $45.00 |
| 2015-10-19 | Reiterated Rating | Jefferies Group | Buy | $63.00 |
| 2015-10-09 | Reiterated Rating | Piper Jaffray | Buy | |
| 2015-10-08 | Reiterated Rating | Cowen and Company | Buy | $55.00 |
| 2015-10-08 | Boost Price Target | Piper Jaffray | Overweight | $86.00 to $96.00 |
| 2015-10-08 | Reiterated Rating | JPMorgan Chase & Co. | Buy | |
| 2015-10-08 | Reiterated Rating | Robert W. Baird | Buy | $64.00 to $66.00 |
| 2015-10-08 | Reiterated Rating | Leerink Swann | Outperform | $67.00 to $71.00 |
| 2015-09-17 | Reiterated Rating | Robert W. Baird | Outperform | $64.00 to $54.00 |
| 2015-09-16 | Reiterated Rating | Piper Jaffray | Overweight | $82.00 to $86.00 |
| 2015-09-16 | Boost Price Target | Robert W. Baird | $64.00 | |
| 2015-09-10 | Reiterated Rating | JPMorgan Chase & Co. | Buy | |
| 2015-08-18 | Initiated Coverage | Jefferies Group | Buy | $39.00 to $61.00 |
| 2015-08-17 | Reiterated Rating | Robert W. Baird | Positive | $54.00 |
| 2015-07-31 | Reiterated Rating | Cowen and Company | Outperform | $45.00 to $55.00 |
| 2015-07-21 | Initiated Coverage | Leerink Swann | Outperform | $67.00 |
| 2015-06-17 | Reiterated Rating | Piper Jaffray | Overweight | $63.00 to $87.00 |
| 2015-06-16 | Boost Price Target | Robert W. Baird | Outperform | $40.00 to $54.00 |
| 2015-05-22 | Boost Price Target | Nomura | Buy | $61.00 to $69.00 |
| 2015-05-22 | Boost Price Target | Piper Jaffray | Overweight | $56.00 to $64.00 |
| 2015-03-19 | Initiated Coverage | JPMorgan Chase & Co. | Overweight | $54.00 |
| 2015-03-04 | Initiated Coverage | Barclays | Overweight | $60.00 |
| 2015-03-04 | Initiated Coverage | Barclays PLC | Overweight | $60.00 |
| 2015-03-02 | Set Price Target | Piper Jaffray | Buy | $56.00 |
| 2015-02-10 | Boost Price Target | Deutsche Bank | Buy | $35.00 to $45.00 |
| 2015-02-05 | Initiated Coverage | RBC Capital | Outperform | $40.00 |
| 2015-02-05 | Initiated Coverage | Royal Bank Of Canada | Outperform | $40.00 |
| 2015-02-04 | Initiated Coverage | Robert W. Baird | Outperform | $40.00 |
| 2015-01-20 | Boost Price Target | Jefferies Group | Buy | $32.00 to $39.00 |
| 2015-01-09 | Boost Price Target | Jefferies Group | Buy | $24.00 to $32.00 |
| 2015-01-08 | Reiterated Rating | Deutsche Bank | Buy | $25.00 to $35.00 |
| 2015-01-06 | Boost Price Target | Nomura | Buy | $34.00 |
| 2014-12-16 | Boost Price Target | Piper Jaffray | Top Pick to Top Pick | $26.00 to $29.00 |
| 2014-11-04 | Reiterated Rating | MKM Partners | Buy | $20.00 to $22.00 |
| 2014-04-24 | Reiterated Rating | Nomura | Buy | $23.00 |
| 2014-02-10 | Boost Price Target | Oppenheimer | Outperform | $15.00 to $19.00 |
| 2014-02-07 | Boost Price Target | MKM Partners | Buy | $17.00 to $20.00 |
| 2014-02-07 | Boost Price Target | Roth Capital | $22.00 to $24.00 | |
| 2014-02-07 | Boost Price Target | Cowen and Company | $19.00 to $20.00 | |
| 2014-01-08 | Initiated Coverage | Nomura | Buy | |
| 2014-01-08 | Downgrade | Morgan Stanley | Overweight to Equal Weight | $16.00 |
| 2014-01-08 | Boost Price Target | Jefferies Group | $16.00 to $23.00 | |
| 2014-01-07 | Boost Price Target | MKM Partners | Buy | $13.00 to $17.00 |
| 2014-01-07 | Boost Price Target | Deutsche Bank | Buy | $18.00 to $25.00 |
| 2014-01-07 | Boost Price Target | Roth Capital | $16.00 to $22.00 | |
| 2013-12-19 | Initiated Coverage | Piper Jaffray | Overweight | $17.00 |
| 2013-08-29 | Reiterated | Deutsche Bank | Buy | $15 to $25 |
| 2013-06-19 | Initiated | Oppenheimer | Outperform | $16 |
| 2013-02-11 | Reiterated | MKM Partners | Buy | $11.50 to $15 |
| 2011-08-09 | Initiated | MKM Partners | Buy | $12 |
| 2008-10-30 | Upgrade | Piper Jaffray | Sell to Neutral | |
| 2008-09-04 | Reiterated | UBS | Neutral | $5.50 to $6 |
| 2007-12-17 | Reiterated | Lehman Brothers | Overweight | $19 to $9.50 |
| 2007-12-14 | Reiterated | UBS | Neutral | $11 to $6 |
| 2007-12-14 | Downgrade | Bear Stearns | Peer Perform to Underperform | |
| 2007-12-13 | Reiterated | Jefferies & Co | Underperform | $5 to $4 |
| 2007-10-11 | Initiated | Wachovia | Mkt Perform |
| 2016-06-29 | Initiated Coverage | HC Wainwright | Buy | $80.00 |
| 2016-06-08 | Reiterated Rating | Jefferies Group | Buy | |
| 2016-06-07 | Reiterated Rating | Piper Jaffray | Overweight | $96.00 |
| 2016-06-07 | Reiterated Rating | Piper Jaffray Cos. | Overweight | $96.00 |
| 2016-06-01 | Reiterated Rating | Leerink Swann | Outperform | $63.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In NBIX 336 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| BlackRock Inc. | 12.05M |
| Vanguard Group, Inc | 9.00M |
| HENDERSON GROUP PLC | 4.93M |
| JANUS CAPITAL MANAGEMENT LLC | 4.36M |
| STATE STREET CORP | 3.77M |
| JPMORGAN CHASE & CO | 2.37M |
| BlackRock Institutional Trust Company, N.A. | 2.27M |
| BlackRock Fund Advisors | 2.12M |
| PICTET ASSET MANAGEMENT LTD | 1.72M |
| DEERFIELD MANAGEMENT CO | 1.51M |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.46M |
| RENAISSANCE TECHNOLOGIES LLC | 1.44M |
| EATON VANCE MANAGEMENT | 1.35M |
| ARMISTICE CAPITAL, LLC | 1.32M |
| DSM CAPITAL PARTNERS LLC | 1.32M |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| BVF PARTNERS L P/IL | 4.65% (3527700) | ARQL / ARRY / CAPS / CCXI / CNCE / CTIC / INFI / LGND / NBIX / ONTY / PTN / RGDO / RGEN / RIGL / TRGT / XENE / |
| GORMAN KEVIN CHARLES President and CEO | 0.46% (347033) | NBIX / XNCR / |
| LYONS GARY A | 0.36% (275697) | CYTX / KBIO / NBIX / PDLI / RIGL / TKAI / VICL / |
| Coughlin Timothy P VP and Chief Financial Officer | 0.18% (137961) | FATE / NBIX / |
| Bozigian Haig P. Sr Vice President, Development | 0.18% (135997) | NBIX / |
| VALEUR JENSEN MARGARET E EVP and General Counsel | 0.16% (118256) | NBIX / |
| Grigoriadis Dimitri E. Vice President, Research | 0.11% (82942) | NBIX / |
| Gano Kyle Chief Business Dev Officer | 0.10% (78742) | NBIX / |
| SHERWIN STEPHEN A | 0.08% (57548) | BIIB / NBIX / RIGL / VICL / VSTM / |
| MOLLICA JOSEPH A | 0.08% (57354) | CPXX / NBIX / |
| OBrien Christopher Flint Sr. VP & Chief Medical Officer | 0.07% (55946) | NBIX / |
| Nevinny Corinne H | 0.06% (48283) | AVNR / NBIX / |
| POPS RICHARD F | 0.06% (43259) | ALKS / EPZM / NBIX / XLRN / |
| RASTETTER WILLIAM H | 0.03% (24750) | CERU / FATE / ILMN / NBIX / RCPT / RGLS / |
| Lippoldt Darin Chief Legal Officer | 0.02% (16062) | NBIX / VOLC / |
| NEUROCRINE BIOSCIENCES INC | 0.02% (16030) | NBIX / |
| MITCHELL W THOMAS | 0.02% (16000) | NBIX / |
| Lloyd-Smith Malcolm Chief Regulatory Officer | 0.02% (15318) | CADX / NBIX / |
| BENEVICH ERIC Chief Commercial Officer | 0.01% (4310) | NBIX / |
UM